CD40 and neoplasm: For example, the finding that the location of immune activation is associated with distinct outcomes, i.e., antitumor activity vs. systemic toxicity, advanced approaches aiming to direct CD40 agonism selectively to the tumor microenvironment (TME) to avoid toxicity.